...
首页> 外文期刊>Die Pharmazie >A modulatory effect of novel kojic acid derivatives on cancer cell proliferation and macrophage activation.
【24h】

A modulatory effect of novel kojic acid derivatives on cancer cell proliferation and macrophage activation.

机译:新型曲酸衍生物对癌细胞增殖和巨噬细胞活化的调节作用。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

We examined whether several newly synthesized derivatives of kojic acid, a compound with known antiinflammatory, anti-proliferative, and anti-oxidative properties, were able to modulate glioma cell proliferation and Toll-like receptor (TLR) 4-mediated functional activation of macrophage-managed tumor microenvironments. Anti-cancer effects on C6 glioma and SYF cells were examined by cell proliferation assays, DNA laddering assays, nuclear staining experiments, and Western blot analysis. The anti-inflammatory activities of the derivatives were assessed by measuring the production of nitric oxide (NO) and cytokine expression in macrophages (RAW264.7 cells) stimulated with the TLR 4 ligand lipopolysacchride (LPS). Among the various derivatives tested, RHS-0110 exhibited the strongest inhibitory activity on the proliferation of C6 glioma cells, with an IC50 value of 4.7 microM. However, the inhibitory effect of this compound was abrogated with respect to the proliferation of SYF cells, a cell line lacking Src, Yes, and Fyn kinases, similar to effects observed with the Src kinase inhibitor PP2. In agreement with these findings, RHS-0110 decreased the expression of Src but not the activation of Yes and Fyn. Based on DNA laddering tests and nucleus staining experiments, the anti-proliferative effects of RHS-0110 appeared to be due to a necrotic pathway. Kojic acid derivatives also suppressed LPS-induced NO production and interleukin (IL)-6 expression in RAW264.7 cells under lowered or non-cytotoxic concentrations of compounds. Because of their anti-proliferative and anti-TLR4-mediated microenvironmental formation features, our results suggest that kojic acid derivatives, including RHS-0110, may be useful as novel anti-cancer drugs.
机译:我们检查了几种新合成的曲酸衍生物(一种具有已知抗炎,抗增殖和抗氧化特性的化合物)是否能够调节神经胶质瘤细胞增殖和Toll样受体(TLR)4介导的巨噬细胞-功能激活。管理的肿瘤微环境。通过细胞增殖测定,DNA梯形测定,核染色实验和蛋白质印迹分析检查了对C6胶质瘤和SYF细胞的抗癌作用。通过测量由TLR 4配体脂多糖(LPS)刺激的巨噬细胞(RAW264.7细胞)中一氧化氮(NO)的产生和细胞因子表达来评估衍生物的抗炎活性。在测试的各种衍生物中,RHS-0110对C6胶质瘤细胞的增殖表现出最强的抑制活性,IC50值为4.7 microM。但是,就SYF细胞(缺乏Src,Yes和Fyn激酶的细胞系)的增殖而言,该化合物的抑制作用已被取消,与使用Src激酶抑制剂PP2观察到的作用相似。与这些发现一致,RHS-0110减少了Src的表达,但没有激活Yes和Fyn。根据DNA梯形测试和细胞核染色实验,RHS-0110的抗增殖作用似乎是由于坏死途径所致。在降低或无细胞毒性的化合物浓度下,曲酸衍生物还抑制RAW264.7细胞中LPS诱导的NO生成和白介素(IL)-6表达。由于它们具有抗增殖和抗TLR4介导的微环境形成的功能,我们的结果表明,曲酸衍生物(包括RHS-0110)可用作新型抗癌药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号